Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Inflammatory Indication Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for COLEC11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | COLEC11 Recombinant Protein (HEK293-expressed, ensuring native glycosylation and correct disulfide-linked oligomerization). High purity (>95%), Endotoxin Controlled (<1.0 EU/μg), Sequence Verified. | View COLEC11 Products |
| Gene Delivery | COLEC11 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction and expression validation. | View COLEC11 Products |
| Benchmark Ab | Anti-COLEC11 Recombinant Antibody. High-affinity positive control for ligand-blocking and ELISA assay development. | View COLEC11 Products |
| Validator | COLEC11 siRNA Set. Optimized pool for target knockdown verification in primary renal or ocular cell models. | View COLEC11 Products |
| Related Target A | COLEC10 (Collectin-10 / CL-L1). Forms functional heteromeric complexes (CL-LK) with COLEC11 in vivo; essential for physiological lectin pathway assays. | View COLEC10 Products |
| Related Target B | MASP3 (MBL-Associated Serine Protease 3). Primary functional partner recruited by COLEC11 to trigger the alternative/lectin complement amplification loop. | View MASP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Oligomeric State Mimicry (CL-LK heteromerization) | HEK293 co-expression compatible COLEC11 and COLEC10 proteins, preserving native coiled-coil and collagen-like domains. |
| Calcium-Dependent Ligand Binding Validation | Strictly controlled formulation buffer optimized for functional carbohydrate-binding assays (e.g., L-fucose binding). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positives | Sequence-verified siRNA sets included for target specificity validation in cell-based models. |
Live COLEC11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for COLEC11 therapeutics is intensifying, with major players shifting focus from broad complement inhibitors (e.g., C3/C5 blockers) to highly specific upstream lectin pathway modulators. COLEC11 (Collectin-11 / CL-K1) represents a critical initiator of the complement cascade during tissue injury. As first-generation therapies targeting the lectin pathway reach late-stage clinical evaluation, the next wave of R&D is targeting the specific blocking of COLEC11-mediated recognition of ischemic tissues to prevent acute kidney injury (AKI) and renal ischemia-reperfusion injury (IRI).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Omeros Corporation, Academic Institutions | Renal Ischemia-Reperfusion Injury (IRI), IgA Nephropathy | Ligand-blocking assay (Requires high-purity, natively glycosylated COLEC11 ECD-Fc) |
| Small Molecule Inhibitors | Biotech Startups | Age-Related Macular Degeneration (AMD), Diabetic Nephropathy | High-throughput screening (Requires stable COLEC11-MASP3 interaction assay components) |
| RNA Therapeutics (siRNA) | Alnylam, Arrowhead (Preclinical exploration) | Chronic Kidney Disease (CKD), Localized Renal Inflammation | Target knockdown validation (Requires sequence-verified siRNA controls and Lentivirus) |